An increasing, potentially measles-susceptible population over time after vaccination in Korea

Kang, Hae Ji; Han, Young Soo; Kim, Su Jin; Kim, You-Jin; Kim, A-Reum; Kim, Joo Ae; Jung, Hee-Dong; Eom, Hye Eun; Park, Ok; Kim, Sung Soon

doi:10.1016/j.vaccine.2017.06.058

Cited by 83 publications

(78 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, seronegativity rates for measles, mumps, rubella, and varicella were 32.5, 37.1, 32.0, and 5.1%, respectively, similar to the rates reported by Naganuma et al [5,6]. In addition, in a study on healthcare workers in major hospitals in Japan, in which seronegativity was defined as IgG < 4 IU/mL by the EIA method, the reported seronegativity rates were 7.4% for measles, 16.1% for mumps, 8.4% for rubella, and 0.8% for varicella [4,[7][8][9][10][11], and when we computed the seronegativity rates of our IBD patients using the same cutoff value, the rate was 3.0% for measles, 37.1% for mumps, 14.1% for rubella, and 5.1% for varicella, indicating higher seronegativity rates for healthcare workers in the general population were for IBD patients, with the exception of measles. Although the difference in assay methods prohibits an accurate comparison, seronegativity rates in Asian countries and 2 European countries are shown in Table 1.…”

Section: Immunization Coverage In Japansupporting

confidence: 81%

Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease

Sagami

Hibi

2018

Inflamm Intest Dis

View full text Add to dashboard Cite

Background: Inflammatory bowel disease (IBD) patients with immunocompromise have a high risk of developing complications related to viral infections. Western countries were the first to formulate vaccine guideline. Asian countries developed their national and international vaccine guidelines a little later in order to reduce the risk of mortality from viral infections. However, no studies to date have examined the differences in vaccinations that prevail among Asian countries. Summary: This review summarizes the vaccination status and schedules in various Asian countries for immunocompromised IBD patients. Vaccination rates, regardless of the specific vaccine, were high in Japan, South Korea, and China and low in India and the Philippines. Vaccine schedules differed by country, and outbreaks of measles and rubella were seen due to low vaccination rates in Southeast Asia and South Asia. Live vaccines cannot be administered during immunosuppressive treatment. Infection with measles, mumps, and varicella during immunosuppressive therapy carries a high risk of mortality, and thus confirmation of immunization status is recommended as soon as IBD is diagnosed and, when possible, live vaccines should be administered before the initiation of immunosuppressive treatment. In patients seronegative for hepatitis B, administration of the hepatitis B vaccine is also recommended. Key Messages: Physicians, while considering severity of outbreaks, should understand the differences in vaccination status that exist among the various Asian countries and regions.

show abstract

Section: Immunization Coverage In Japansupporting

confidence: 81%

Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease

Sagami

Hibi

2018

Inflamm Intest Dis

View full text Add to dashboard Cite

show abstract

“…When individual age groups were compared, antibody titers decreased overtime; 18-29 year-81.1%; 30-39 years; 61.5%. The results of similar study in Korea also indicated a progressive decline of antibody level and seroprotection rates over time among 2-30 years old vaccinated persons (45) . Measles outbreaks investigation indicated that the vaccine failure was observed among 13-44% of measles cases in several large outbreaks, and in an epidemic up to 14% of cases had received at least 2-doses of measles vaccine (7) .…”

Section: Discussionmentioning

confidence: 74%

“…Otherwise, there are evidences that antibody concentrations decline and fall to low or undetectable levels (43)(44)(45) . Considering these evidences, the relative high rates of measles susceptibility observed among our study group B could be attributed to waning of acquired seroprotection over time (SVF) or possibly may be the result of PVF.…”

Section: Discussionmentioning

confidence: 99%

“…The protection rates will increase up to 95-98% after the second dose vaccination and persist for decades (1,3,6,9) , although, may decline over time years after initial immunization (43)(44)(45) . In this study, nearly 12.8% and 17.7% of 7-15 years old subjects (group C and D) who were vaccinated with 2-dose of MMR vaccine administered after the age of 12 months were serologically susceptible to measles and rubella respectively.…”

Section: Discussionmentioning

confidence: 99%

“…and long absence of measles virus transmission (43)(44)(45) . In a prospective multicenter study by Smetana et al (43) , measles lgG antibody concentrations among vaccinated subjects ≥ 18 years was evaluated.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Measles and Rubella Serosusceptibity Among Population Vaccinated with Different Schedule of Vaccination: The Potential Impact on Measles Elimination in Iran.

Saffar¹,

Khalifeloo

Saffar

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background: In addition to schedule 2-doses monovalent measles vaccine (mMV) immunization of Iranian children since 1984, a nationwide campaign of measles-rubella (MR) immunization among 5- 25 years-old population in December 2003 was conducted. From 2004 mMV was replaced with measles- mumps-rubella (MMR) vaccine. Despite a high vaccination coverage, outbreaks of measles occurred in the country. Study was designed to investigate seroimmunity against measles and rubella among various age groups of population who were vaccinated with different schedule since 1984. Also, immunologic response to revaccination in seronegative subjects was evaluated. Methods: From 1 November 2017 to 30 June 2018 a cross- sectional study among 7- 33 year old healthy population with documented history of measles vaccination was conducted. Based on their age and history of vaccination categorized as GA: 20-23 years old; vaccinated with 1-2 dose of mMV, and also MR revaccinated. GB: 15-19 years, vaccinated only with 2- doses of mMV at the ages of 9 and 15 months. GC: 12-14 years and GD: 7-11 years; vaccinated with 2- dose of MMR vaccine at the ages 15 months - 6 years, and 12-18 month respectively. Collected sera were assessed to measure antimeasles and antirubella IgG antibodies concentration. Four to 6 weeks after revaccination of seronegative subjects, antimeasles-antirubella IgM and IgG antibodies were rechecked. Collected data were analyzed using descriptive statistical methods.Results: Totally 635 individuals, 312 female were included. Relative distribution of subjects in each group was as: GA: 98, GB: 295, GC: 139, and GD: 103 persons. Overall, 12.28% and 18.4% of population were soronegative, and varied greatly between groups: 2%-0/0%, 15.2%- 25.0%, 11.5%- 17.2%; and 14.6%-18.4% to measles and rubella, respectively. After revaccination, 92% and 94.9% showed 1gG response to measles and rubella vaccine respectively.Conclusion: Despite high coverage rate with measles containing vaccine, a significant numbers of vaccinated subjects lost their seroprotection, possibly because of secondary vaccine failure. This may affect measles-rubella elimination goal in the country. If these data were confirmed by further studies, more strengthen regional/ national supplementary immunization activity should be considered.

show abstract

Seroprevalence of Measles and Mumps Antibodies Among Individuals With Cancer

et al. 2021

View full text Add to dashboard Cite

IMPORTANCE Although patients with cancer are at an increased risk of infection-related complications, few studies have characterized their vulnerability to measles and mumps. Given the recent outbreaks and increased community vaccine hesitancy, understanding measles and mumps immunity within this population is vital. OBJECTIVESTo identify a point prevalence estimate of protective measles and mumps antibodies among ambulatory patients with cancer. DESIGN, SETTING, AND PARTICIPANTS In this cross-sectional study, residual clinical plasma samples were obtained from consecutive patients with cancer at Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center in Seattle, Washington, in August 2019. These samples were tested for measles and mumps IgG using a commercial enzyme-linked immunosorbent assay. Patients without cancer were excluded from the analysis. EXPOSURES Patient age, sex, self-reported race and ethnicity, primary disease, receipt of chemotherapy in the past 30 days before sample collection, hematopoietic cell transplant (HCT) history, and date of most recent intravenous immunoglobulin treatment were abstracted from electronic medical records. MAIN OUTCOMES AND MEASURES Measles and mumps IgG seroprevalence, defined as the proportion of patients with positive antibody test results, was measured overall and among the subgroups. RESULTSOf the 959 patients included in the analysis, 510 (53%) were male individuals and the mean (SD) age at sample collection was 60 (15) years. Most patients (576 [60%]) had a malignant solid tumor, and 383 patients (40%) had a hematologic malignant neoplasm; 146 patients (15%) had an HCT history. Overall, the seroprevalence of measles antibodies was 0.75 (95% CI, 0.72-0.78), and the seroprevalence of mumps antibodies was 0.62 (95% CI, 0.59-0.65). The lowest seroprevalences were among patients with a hematologic malignant neoplasm (0.63 for measles and 0.48 for mumps), those with a history of HCT (0.46 for measles and 0.29 for mumps), and those aged 30 to 59 years (0.49-0.63 for measles and 0.41-0.58 for mumps). CONCLUSIONS AND RELEVANCEIn this study, 25% of ambulatory patients with cancer lacked protective antibodies for measles and 38% lacked protective antibodies for mumps. Deficits in protective antibodies underscore patients' increased risk during outbreaks and emphasize the need for community-based efforts to increase herd immunity to protect this population.

show abstract

An increasing, potentially measles-susceptible population over time after vaccination in Korea

Cited by 83 publications

References 34 publications

Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease

Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease

Measles and Rubella Serosusceptibity Among Population Vaccinated with Different Schedule of Vaccination: The Potential Impact on Measles Elimination in Iran.

Seroprevalence of Measles and Mumps Antibodies Among Individuals With Cancer

Contact Info

Product

Resources

About